Parenteral Iron Therapy

Article1 December 1964Parenteral Iron TherapyII: A New Iron-sorbitol Citric Acid Complex for Intra-muscular InjectionPAUL R. MCCURDY, M.D.PAUL R. MCCURDY, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-6-1053 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough the majority of patients with iron deficiency anemia can be treated adequately with oral iron compounds, it is occasionally necessary to resort to parenteral medication. The indications for administering iron by injection include chronic bleeding with a need for rapid repletion of stores, malabsorption of iron from the gastrointestinal tract, and intolerance of oral iron compounds. Despite the definite need for a parenteral iron medication, an entirely suitable and safe injectable preparation has not been developed.Initial attempts at therapy with ionizable iron salts led to serious reactions. Subsequently, poorly ionizable complexes have been examined for their clinical usefulness....References1. BROWNMOORE EBCV: Parenterally administered iron in the treatment of hypochromic anemia, in Progress in Hematology, Volume 1, edited by Tocantins, L. M. Grune and Stratton, New York, 1956, pp. 22-46. Google Scholar2. MCCURDYRATHMEERKREBS PRCEGE: Parenteral iron therapy: with special reference to a new preparation for intramuscular injection. New Eng. J. Med. 258: 1147, 1957. CrossrefGoogle Scholar3. RICHMOND HG: Induction of sarcoma in the rat by iron-dextran complex. Brit. Med. J. 1: 947, 1959. CrossrefMedlineGoogle Scholar4. LUNDIN PM: Carcinogenic action of complex iron preparations. Brit. J. Cancer 15: 838, 1961. CrossrefMedlineGoogle Scholar5. FIELDING J: Sarcoma induction by iron-carbohydrate complexes. Brit. Med. J. 1: 1800, 1962. CrossrefMedlineGoogle Scholar6. LINDVALLANDERSSON SNS: Studies on a new intramuscular haematinic, iron-sorbitol. Brit. J. Pharmacol. 17: 358, 1961. Google Scholar7. SVARD PO: Some pharmacologic properties of a new intramuscular iron preparation. J. Pharm. Pharmacol. 13: 641, 1961. CrossrefMedlineGoogle Scholar8. SVARDLINDVALL POS: Mechanism of absorption of two intramuscular iron preparations. J. Pharm. Pharmacol. 13: 650, 1961. CrossrefMedlineGoogle Scholar9. PETERSGIOVANNIELLOAPTROSS TTJLJF: A simple improved method for the determination of serum iron, II. J. Lab. Clin. Med. 48: 280, 1956. MedlineGoogle Scholar10. RESSLERZAK NB: Serum unsaturated iron binding capacity. Amer. J. Clin. Path. 30: 87, 1958. CrossrefGoogle Scholar11. RATHFINCH CECA: Sternal marrow hemosiderin: method for determination of available iron stores in man. J. Lab. Clin. Med. 31: 81, 1948. Google Scholar12. BRECHERSCHNEIDERMAN GMA: Time saving device for counting of reticulocytes. Amer. J. Clin. Path. 20: 1079, 1950. CrossrefMedlineGoogle Scholar13. ANDERSSON NS: Clinical investigations on a new intramuscular haematinic. Brit. Med. J. 2: 275, 1961. CrossrefMedlineGoogle Scholar14. PRINGLEGOLDBERGMACDONALDJOHNSTON AAES: 59Fe-iron sorbitol citric acid complex in iron deficiency anemia. Lancet 2: 749, 1962. CrossrefMedlineGoogle Scholar15. FIELDING J: Experimental and clinical observations on iron-sorbitol-citric acid complex. Presented at the IX Congress of the International Society of Hematology, Mexico City, D. F., Sept. 12, 1962. Google Scholar16. VANSLYCK ET: Clinical experience with iron sorbitol, a new intramuscular iron medication. Amer. J. Med. Sc. 245: 176, 1963. MedlineGoogle Scholar17. AWAIBROWN MEB: Studies of the metabolism of I131 labeled human transferrin. J. Lab. Clin. Med. 61: 363, 1963. MedlineGoogle Scholar18. WETHERLEY-MEINBUCHANANGLASSPEARCE GJGUHLC: Metabolism of 59Fe-sorbitol complex in man. Brit. Med. J. I: 1796, 1962. CrossrefGoogle Scholar19. GRIMESHUTT AJMS: Metabolism of 59Fe dextran complex in human subjects. Brit. Med. J. 2: 1074, 1957. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PAUL R. MCCURDY, M.D.Affiliations: Washington, D. C.From the Georgetown Medical Division, District of Columbia General Hospital, Washington, D. C., and the Department of Medicine, Georgetown University School of Medicine, Washington, D. C.This work was supported in part by a grant from Astra Pharmaceutical Products, Inc., Worcester, Mass.Requests for reprints should be addressed to Paul R. McCurdy, M.D., D. C. General Hospital, 19th and E Streets, S. E., Washington 3, D. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLoss of Taste, Smell, and Other Senses with AgeTaste and smell perception in the elderly: Effect of medications and diseaseTaste and Smell in DiseaseIron DeficiencyTeratological, Peri- and Postnatal Studies on Ferastral®, an Iron-poly (sorbitol-gluconic acid) complexBiopharmaceutical Considerations in Subcutaneous and Intramuscular Drug AdministrationFatal Anaphylaxis After Intramuscular Iron-DextranCHARLES E. BECKER, M.D., ROB R. MACGREGOR, M.D., KEITH S. WALKER, M.D., JAMES H. JANDL, M.D.CHAPTER iii: DISTRIBUTION AND UTILIZATION OF Fe59-LABELLED IRON-SORBITOLCITRIC ACID (JECTOFER) IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTHY CONTROLS 1 December 1964Volume 61, Issue 6Page: 1053-1064KeywordsAnemiaGastrointestinal tractHemoglobinHemorrhageHospital medicineIntoxicationIron deficiency anemiaNauseaProteinsSalts ePublished: 1 December 2008 Issue Published: 1 December 1964 PDF downloadLoading ...